Baird Raises Price Target for Charles River Laboratories to $334

Baird has increased its price target for Charles River Laboratories International, Inc., a global provider of drug discovery and development services, from $291 to $334. This adjustment reflects the firm's positive outlook on the company's performance and market position.

The revised price target indicates Baird's confidence in Charles River Laboratories' growth potential, particularly in the context of ongoing demand for biopharmaceutical services. Investors and analysts will be closely monitoring the company's developments following this upgrade.

© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: KLEA News